Celldex Therapeutics CLDX Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Celldex Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The official record: Celldex Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Celldex Therapeutics's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Celldex Therapeutics's cash & equivalents?
- Celldex Therapeutics (CLDX) reported cash & equivalents of $35.73M in Q1 2026.
- How has Celldex Therapeutics's cash & equivalents changed year-over-year?
- Celldex Therapeutics's cash & equivalents increased by 108.5% year-over-year, from $17.14M to $35.73M.
- What is the long-term trend for Celldex Therapeutics's cash & equivalents?
- Over 5 years (2020 to 2025), Celldex Therapeutics's cash & equivalents has grown at a -8.0% compound annual growth rate (CAGR), from $43.84M to $28.87M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.